ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook

13 May 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit

07 May 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021

06 May 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development

05 May 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference

26 Apr 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome

12 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference

08 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021

07 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

31 Mar 2021 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

16 Mar 2021 06:00:01 By Nasdaq GlobeNewswire